Researchers have built one of the most detailed maps yet of how B cells, the white blood cells responsible for making antibodies, develop and behave inside melanoma tumors. The study, led by King's College London and published in the Journal of Experimental & Clinical Cancer Research, sheds light on how these cells develop, organize and interact within melanoma tumors before and after immunotherapy.

There are currently no reliable biomarkers to predict which melanoma patients will respond to immunotherapy, and the team hopes its findings could eventually help guide treatment decisions and improve outcomes.

B cells are commonly found in both early and advanced melanoma and change over time, often appearing alongside other immune cells in specialized hubs within tumors called tertiary lymphoid structures. Much about their development, location, and function in melanoma has remained poorly understood, including their influence on immunotherapy response.

To build their picture, researchers combined several advanced technologies, analyzing blood and tumor samples from patients treated at Guy's and St Thomas' NHS Foundation Trust alongside external datasets used to validate the results.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The team identified a previously unrecognized "inflamed," or activated, B cell state governed by signaling proteins called interferons. These activated cells persisted throughout disease progression and after immunotherapy, appeared consistently across patients, and were often found near other key immune cells in specialized regions where the immune system builds long-term responses. Over time, B cells within tumors moved from immature forms into more specialized types, including this activated state. 

The researchers also found differences between the B cells of responders and non-responders to immunotherapy: tumors from responders were more likely to contain B cell populations tied to organized immune responses, though larger studies are needed to confirm this. Melanoma tumors also contained B cells producing different types of antibodies, with B cell responses continuing to evolve after immunotherapy. 

Professor Sophia Karagiannis, co-senior author, said the work provides “one of the most detailed pictures to date of B cell behavior in melanoma” and highlights “the remarkable complexity of immune activity within the tumour microenvironment.” The team, she added, “identified previously underappreciated B cell states that persist through disease progression and after immunotherapy,” offering "new clues about how the immune system adapts within tumors.”

Co-senior author Dr Sophia Tsoka said the team integrated bulk sequencing, single-cell, spatial transcriptomic, and antibody sequencing data, since no single dataset can capture the full complexity of the tumor immune environment, which “transformed fragmented observations into a coherent biological picture” revealing how B cells develop in cancer and relate to clinical outcomes.